Vertex Pharmaceuticals (VRTX)

• Market cap: $127B
• 1 day: 1.19%
• 5 days: 3.47%
• 1 month: 5.09%
• 3 months: 16.22%
• 6 months: 7.25%
• Year to date: 25.57%
• 1 year: 29.71%
• 5 years: 102.83%
• 10 years: 313.29%
• Sector: Healthcare
• Industry: Biotechnology

About: Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Employees: 6,100

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

24% more first-time investments, than exits

New positions opened: 191 | Existing positions closed: 154

11% more call options, than puts

Call options by funds: $780M | Put options by funds: $700M

2.03% more ownership

Funds ownership: 89.52% [Q3] → 91.54% (+2.03%) [Q4]

0% more funds holding

Funds holding: 1,526 [Q3] → 1,529 (+3) [Q4]

10% less repeat investments, than reductions

Existing positions increased: 546 | Existing positions reduced: 605

11% less capital invested

Capital invested by funds: $107B [Q3] → $95.5B (-$11.8B) [Q4]

45% less funds holding in top 10

Funds holding in top 10: 29 [Q3] → 16 (-13) [Q4]

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $420 18% downside
• Avg. target: $487 4% downside
• High target: $567 11% upside

10 analyst ratings

• positive: 5 50%
• neutral: 5 50%
• negative: 0 0%

Cantor Fitzgerald Carter Gould 39% 1-year accuracy 12 / 31 met price target	5% upside $535	Overweight Assumed	22 Apr 2025
RBC Capital Brian Abrahams 19% 1-year accuracy 13 / 70 met price target	18% downside $420	Sector Perform Maintained	1 Apr 2025
B of A Securities Ying Huang 100% 1-year accuracy 3 / 3 met price target	11% upside $567	Buy Maintained	31 Mar 2025
Canaccord Genuity Whitney Ijem 34% 1-year accuracy 15 / 44 met price target	17% downside $424	Hold Upgraded	12 Feb 2025
Truist Securities Joon Lee 48% 1-year accuracy 20 / 42 met price target	2% upside $520	Buy Maintained	11 Feb 2025